Genialis develops ResponderID, a machine-learning-driven platform that generates predictive biomarkers and molecular portraits from NGS-based data to inform clinical and translational research. The company partners with biopharma to analyze clinical-trial data, inform trial design, and supports commercialization of next‑gen biomarker assays with diagnostic firms. Genialis reports multiple scientific outputs, including ten publications/posters and a co‑authored Journal of Clinical Oncology paper using its models. The company plans to expand its proprietary ResponderID platform and build a comprehensive collection of clinically validated biomarker models to provide pinpoint diagnoses for cancer patients. Genialis is growing teams in both the U.S. and Slovenia and investing in R&D collaborations with cancer centers, hospital groups, and academic labs. Financially, the company announced a Series A round of more than $13 million to fund these product and commercial expansions. Genialis provides SaaS-based biological visual analytics software and an application for variant discovery by targeted genome sequencing. Its system aims to learn how users prefer to interact with their data and to optimize analysis and the user experience based on user-generated content and public data. Early access users on the Expressions and variant discovery apps include researchers from Harvard University, CPMCRI, Johns Hopkins and Jackson Labs. The company is based in Houston, Texas; Cambridge, Massachusetts; and Ljubljana, Slovenia. Genialis recently closed a $2.3M seed funding round. It intends to use the funds to accelerate the team’s expansion in the U.S. and to commercialize its platform.

Total raised

$15M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2023